| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Alto Neuroscience, Inc. | CHIEF OPERATING OFFICER | Employee Stock Option (right to buy) | 188K | $596K | $3.17 | May 20, 2024 | Direct |
| Aeglea BioTherapeutics, Inc. | Chief Business Officer | Common Stock | 36.2K | $20.3K | $0.56 | Jun 8, 2022 | Direct |
| Aeglea BioTherapeutics, Inc. | Chief Business Officer | Employee Stock Option (right to buy) | 500K | Feb 23, 2023 | Direct | ||
| Alto Neuroscience, Inc. | CHIEF OPERATING OFFICER | Employee Stock Option (Right to Buy) | 125K | Feb 5, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ANRO | Alto Neuroscience, Inc. | Feb 5, 2025 | 1 | $0 | 4 | Feb 7, 2025 | CHIEF OPERATING OFFICER |
| ANRO | Alto Neuroscience, Inc. | May 20, 2024 | 1 | $0 | 4 | May 22, 2024 | Chief Operating Officer |
| ANRO | Alto Neuroscience, Inc. | May 20, 2024 | 0 | $0 | 3 | May 22, 2024 | Chief Operating Officer |
| AGLE | Aeglea BioTherapeutics, Inc. | Feb 23, 2023 | 1 | $0 | 4 | Feb 24, 2023 | Chief Business Officer |
| AGLE | Aeglea BioTherapeutics, Inc. | Aug 23, 2022 | 1 | $0 | 4 | Aug 25, 2022 | Chief Business Officer |
| AGLE | Aeglea BioTherapeutics, Inc. | Jun 8, 2022 | 1 | $20K | 4 | Jun 10, 2022 | Chief Commercial Officer |
| AGLE | Aeglea BioTherapeutics, Inc. | Feb 17, 2022 | 1 | $0 | 4 | Feb 22, 2022 | Chief Commercial Officer |